Main Page | Recent changes | View source | Page history

Printable version | Disclaimers | Privacy policy

Not logged in
Log in | Help
 

S. 316-110

From dKosopedia


This article is a stub. You can help dKosopedia by expanding it.

Senate Bill 316 (110th Congress)
A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market.
Sponsor: Sen Kohl, Herb
Committees: Senate Judiciary

Bill Text

Text of S. 316-110

Update Status

S. 316-110A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market.
March 7, 2007: Senate committee/subcommittee actions. Status: Committee on the Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights. Hearings held.

External Links

External links for S. 316
(110th Congress)
S. 316 at DailyKos
S. 316 at Thomas
S. 316 at Billhop
S. 316 at GovTrack
S. 316 at OpenCongress

Source: thomas.gov search

Retrieved from "http://localhost../../../s/2E/_/S._316-110.html"

This page was last modified 12:00, 17 January 2007 by Anonymous user(s) of dKosopedia. Content is available under the terms of the GNU Free Documentation License.


[Main Page]
Daily Kos
DailyKos FAQ

View source
Discuss this page
Page history
What links here
Related changes

Special pages
Bug reports